SECUADO Drug Patent Profile

When do Secuado patents expire, and what generic alternatives are available?

Secuado is a drug marketed by Hisamitsu and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-eight patent family members in nine countries.

The generic ingredient in SECUADO is asenapine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the asenapine profile page.

DrugPatentWatch^® Generic Entry Outlook for Secuado

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 22, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SECUADO

International Patents:	38
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SECUADO

SECUADO is protected by six US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-001	Oct 11, 2019		RX	Yes	Yes			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-003	Oct 11, 2019		RX	Yes	No			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-002	Oct 11, 2019		RX	Yes	No			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-001	Oct 11, 2019		RX	Yes	Yes			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-002	Oct 11, 2019		RX	Yes	No			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-002	Oct 11, 2019		RX	Yes	No			Y

International Patents for SECUADO

When does loss-of-exclusivity occur for SECUADO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

European Patent Office

Japan

Poland

Portugal

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SECUADO around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20150036479	첩부제
Japan	WO2014017594	貼付剤
South Korea	20150036478	첩부제 (ADHESIVE PATCH)
Spain	2681034
Japan	WO2014017593	貼付剤及びその製造方法
Japan	6005741

Supplementary Protection Certificates for SECUADO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0746317	C300461	Netherlands		PRODUCT NAME: ASENAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MALEAAT; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901
0746317	SPC/GB10/046	United Kingdom		PRODUCT NAME: ASENAPINE; REGISTERED: UK EU/1/10/640/001 20100901; UK EU/1/10/640/002 20100901; UK EU/1/10/640/003 20100901; UK EU/1/10/640/004 20100901; UK EU/1/10/640/005 20100901; UK EU/1/10/640/006 20100901
0746317	10C0056	France		PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901

Last updated: April 25, 2026

SECUADO (asenapine) Investment and Fundamentals Analysis

SECUADO (asenapine) is an oral sublingual branded antipsychotic in the US for schizophrenia and bipolar disorders, with a patent landscape shaped by early origin intellectual property, later formulation/second-generation protections, and the erosion cycle typical of mature CNS assets. The investment case is driven less by clinical differentiation and more by (1) label breadth and persistence of use, (2) share capture and payer positioning versus generics of asenapine, and (3) the remaining duration and enforceability of any formulation or method-of-use IP layers that can keep branded economics intact.

What is SECUADO’s product and label footprint?

SECUADO is an asenapine product intended for sublingual administration. In the US, asenapine has long been an established CNS platform molecule; SECUADO is the branded product that competes with other asenapine presentations and with payer-driven substitution.

US label scope (high-level):

• Indications include schizophrenia in adults
• Indications include manic or mixed episodes associated with bipolar I disorder, and maintenance strategies aligned with bipolar I use patterns (label details vary by specific indication language)

The investment implication is straightforward: asenapine class demand is durable, but branded pricing power depends on how quickly payers switch to lower-cost asenapine alternatives once biosimilar-style price competition is replaced by generic competition dynamics.

Why does SECUADO’s IP matter for investment returns?

For a branded CNS drug whose active ingredient has a long history, investor sensitivity centers on whether remaining protections delay generic substitution and whether any “evergreening” assets are enforceable and meaningfully different from the original compound IP.

For SECUADO, the core questions are:

1. Is there enforceable, unexpired patent coverage specific to SECUADO’s formulation, dosing regimen, or manufacturing method?
2. Do those patents have realistic claim scope against likely ANDA designs?
3. Is there a clear regulatory exclusivity pathway (for example, 505(b)(2) or switch-related exclusivities) that delays first generic entry?
4. Do any Orange Book listed patents for SECUADO have remaining term long enough to impact the branded revenue curve?

What does the competitive landscape look like for asenapine-based assets?

SECUADO competes in a crowded atypical antipsychotic market where:

• Multiple branded and generic antipsychotics exist
• Payers frequently steer to the lowest-cost equivalent with acceptable adherence and tolerability
• Switching behavior accelerates once generic availability and rebate structures shift

For an asenapine-branded product, the key variable is whether SECUADO’s commercial position is protected by IP or by payer contracting tactics that still clear the hurdle after generic entry.

---

Investment Thesis

What are the core drivers of SECUADO revenue durability?

SECUADO durability depends on four fundamentals categories.

1) Patent and market exclusivity

• The branded economics persist only if generic substitution is delayed or constrained.
• If the remaining IP shelf life is short, the investment case must lean on near-term cash flow rather than long-duration growth.

2) Payer behavior and formulary status

• CNS utilization is high-inertia once a patient stabilizes on a therapy.
• Payer step edits and brand-to-generic incentives determine how much that inertia converts to continued SECUADO penetration.

3) Clinical practice fit

• Asenapine dosing convenience, tolerability profile, and sublingual administration logistics affect adherence.
• Real-world prescribing and switching thresholds matter more than incremental efficacy claims.

4) Sales execution and rebate economics

• In mature CNS markets, gross-to-net is a major determinant.
• Any brand premium must clear the payer’s cost-effectiveness threshold.

What is the main risk to the investment case?

The investment risk is generic encroachment once SECUADO’s relevant IP layers expire or are successfully designed around. For mature CNS products, once substitution begins, branded market share typically declines rapidly unless the product has structurally different performance, dosing that reduces discontinuation, or enforceable IP against generic candidates.

---

Fundamentals Framework (Business-usable)

How should investors underwrite SECUADO?

Underwriting should align to a “time-to-generic” and “share retention” model rather than relying on clinical novelty.

Base case mechanics (conceptual, not speculative):

1. Model branded net sales with a generic entry date assumption based on the Orange Book and any enforceable continuation patents.
2. Apply a share erosion curve informed by historical generic substitution patterns in CNS.
3. Discount expected net prices using a gross-to-net framework typical for CNS rebates.
4. Stress test scenarios for early generic entry (IP challenge success) and delayed entry (injunctions or longer patent term through continuation strategy).

Which metrics are most relevant to diligence?

Investors should focus on:

• Orange Book patent listing structure (composition/formulation/method-of-use/process)
• Remaining patent term distribution and claim coverage likelihood against generic ANDA designs
• Gross-to-net trend and whether payer pressure increases ahead of patent cliffs
• Formulary placement (preferred vs non-preferred, prior authorization requirements)
• Persistence and adherence in real-world claims data (proxy metrics: refill rates, discontinuation rates)

---

Commercial and Competitive Positioning

How does SECUADO likely compete on value?

Value capture in CNS is usually split between:

• Clinical comfort with established efficacy
• Tolerability and adherence outcomes
• Payer economics via contracts and rebates
• Switching friction for stable patients

If SECUADO is in a position where prescribers and patients already accept the therapy, the brand’s commercial advantage can persist for a period even after generic launches, but typically shrinks as formularies and rebate structures tilt to generics.

What is the likely impact of generic entry on pricing?

Generic entry typically triggers:

• Lower branded net prices over time due to payer renegotiations
• Higher rebate demands
• Contracted shifts to generic substitution with brand only for prior authorization exceptions

This makes the IP timeline and enforcement path the most investable lever.

---

Catalysts and Timeline Logic

What events tend to move SECUADO’s valuation?

For branded CNS products, market repricing tends to follow:

• FDA regulatory milestones for competitors (e.g., ANDA acceptance, amendments, final approval dates)
• Litigation milestones (trial outcomes, appeal decisions, consent judgments)
• Settlement terms that define “launch-to-launch” effective entry timing
• Label changes that alter prescriber behavior (less common for mature assets)

---

Key Takeaways

• SECUADO is a mature asenapine-branded CNS asset; investor upside depends primarily on how long SECUADO’s specific IP and regulatory exclusivity delay generic substitution.
• Competitive pressure is structurally high in atypical antipsychotics; branded economics increasingly hinge on gross-to-net management and payer positioning rather than differentiated clinical claims.
• The most decision-relevant diligence is the Orange Book patent map: remaining term, claim scope, and enforceability against likely generic designs.
• Valuation is best underwritten using a “generic entry and share erosion” model tied to enforceable IP duration, not long-duration growth narratives.
• The primary risk is generic encroachment through IP expiration or successful design-around during ANDA development or litigation.

---

FAQs

1) Is SECUADO’s investment case driven more by IP than by clinical differentiation?

Yes. For a long-established active ingredient in a crowded class, the economic ceiling is typically governed by the patent and regulatory path that determines time to generic substitution.

2) What diligence item is most important for SECUADO?

The Orange Book listing for SECUADO and the remaining term of the listed patents most likely to block generic entry.

3) How do payers typically treat branded asenapine products after generic availability?

Payer contracts and formularies usually shift to cost-minimizing strategies, driving lower branded net prices and reduced share unless specific exceptions apply.

4) What commercial metric best predicts continued branded penetration?

Persistence and refill behavior in stable patients, combined with formulary placement and prior authorization requirements.

5) What are the valuation-moving catalysts for SECUADO?

Regulatory milestones for generic competitors, litigation and settlement outcomes that define entry timing, and any label expansion that changes prescribing behavior.

---

References (APA)

[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. Food and Drug Administration). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] FDA. SECUADO (asenapine) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/